Patients in the 50- to 59-year-old age range should receive vaccination against shingles, according to the latest recommendation from the Advisory Committee on Immunization Practices (ACIP). That guidance accompanied a rare—and nearly evenly split—nod to one vaccine over another. In an 8-7 vote, ACIP recommended the recently approved Shingrix (GlaxoSmithKline) over Zostavex (Merck). Both vaccines are FDA-approved for use in patients 50 and over, but ACIP recommends Zostavex only in patients over the age of …
Read More